With the exception of a new buyout-focused diagnostics company, it seemed to be the week for relatively small deals for San Diego’s life sciences companies. Here’s my roundup.
—Former Gen-Probe CEO Carl Hull and strategist Eric Tardif have formed Maravai Life Sciences and entered into a partnership with GTCR, a Chicago private equity firm, to acquire companies and products focused on in vitro testing and diagnostics, lab services, and related life sciences tools. After raising a new $3.3 billion fund, GTCR will invest up to $300 million to support Maravai’s roll-up strategy.
—San Diego medical software developer CorTechs Labs has secured $1.2 million from investors, according to a recent regulatory filing. In a statement, the company said the Series B round of financing, led by the Malaysian investment holding company Genting Berhad through its wholly-owned subsidiary, Dragasac Ltd., is intended to accelerate development of the company’s brain atrophy analysis software, and to expand its sales and marketing initiatives.
—Digirad (Nasdaq: DRAD), a diagnostic imaging services provider based in Poway, CA, said it acquired certain assets of Memphis, TN-based Telerhythmics, a 24-hour cardiac event monitoring service used by hospitals and physician offices. Digirad CFO Jeffry Keyes said in an e-mail that Digirad paid $3.47 million in cash, and assumed $131,000 in debt. Digirad provides in-office nuclear gamma cameras used in cardiology imaging, ultrasound imaging services, and cardiac event monitoring services to physician practices, hospitals and imaging centers.
—AMN Healthcare Service (NYSE: AHS), the San Diego-based provider of healthcare nursing and healthcare staffing services, said it made a $5 million strategic investment in PipelineRx, a San Francisco-based telepharmacy company. PipelineRx uses a … Next Page »